Open house contracts for various active ingredients until 30.09.2025.
In the open house procedure, medicinal products are excluded in accordance with the BfArM list according to § 35 para. 5a SGB V (paediatric medicinal products).
Botulinumtoxin Typ A, ATC-Code: M03AX21The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Paracetamol, ATC-Code: N02BE01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Sapropterin, ATC-Code: A16AX07The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Tacrolimus, ATC-Code: L04AD02The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Trientin, ATC-Code: A16AX12The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Vedolizumab, ATC-Code: L04AA33The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Zidovudin, ATC-Code: J05AF01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Zidovudin-Lamivudin-Abacavir, ATC-Code: J05AR04The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Calcipotriol+Betamethason, ATC-Code: D05AX22The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Colistimethat-Natrium, ATC-Code: J01XB01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Diltiazem, ATC-Code: C08DB01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Eculizumab, ATC-Code: L04AA25The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Fluorouracil, ATC-Code: D11AF05The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Folsäure, ATC-Code: B03BB01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Immunoglobulins, normal human, for extravascular, ATC code: J06BA01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.
Nilotinib, ATC-Code: L01EA03The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a para. 8 SGB V for the mentioned active ingredient offered. The earliest start of the contract is 01.10.2023, the end of the contract is 30.09.2025. It is possible to join this open house procedure at any time during the term of the contract.